Market Place
Sourcing Support
Starton Therapeutics Announces Patent Allowance for Lenalidomide
29 Oct 2024 //
GLOBENEWSWIRE
Starton Therapeutics CEO Honored by Icla da Silva Foundation 2024
24 Sep 2024 //
GLOBENEWSWIRE
Starton Demonstrates STAR-LLD With BD Evolve Injector
18 Sep 2024 //
GLOBENEWSWIRE
Starton Therapeutics Strengthens Clinical Development Strategy
22 Aug 2024 //
GLOBENEWSWIRE
Starton Therapeutics 100% Partial Response in Multiple Myeloma STAR-LLD Phase 1b
21 Jun 2024 //
GLOBENEWSWIRE
USPTO Grants Patent For Olanzapine Vomiting/Nausea Treatment
20 May 2024 //
GLOBENEWSWIRE
Starton Completes STAR-LLD Multiple Myeloma Enrollment
25 Apr 2024 //
GLOBENEWSWIRE
Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences
25 Mar 2024 //
GLOBENEWSWIRE
Starton Therapeutics to Present at BIO CEO & Investor Conference 2024
23 Feb 2024 //
GLOBENEWSWIRE
Starton Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial
14 Feb 2024 //
GLOBENEWSWIRE
Starton Therapeutics Announces STARTICLES Filing
17 Jan 2024 //
GLOBENEWSWIRE
Starton Announces Initial Key Safety and Efficacy Signals with STAR-LLD
03 Jan 2024 //
GLOBENEWSWIRE
Starton Announces the Launch of STARSILON a Transdermal PATCH Platform
02 Jan 2024 //
GLOBENEWSWIRE
Starton Therapeutics to Present at Biotech Showcase 2024 in San Francisco
18 Dec 2023 //
GLOBENEWSWIRE
Starton Therapeutics Completes One Third of STAR-LLD Study Enrollment
20 Nov 2023 //
GLOBENEWSWIRE
Starton Announces Termination of Agreement with Healthwell Acquisition
03 Nov 2023 //
BUSINESSWIRE
Starton Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Trial
04 Oct 2023 //
BUSINESSWIRE
Starton Announces the Opening of Site for STAR-LLD Lenalidomide Phase 1b Trial
13 Sep 2023 //
BUSINESSWIRE
Starton Contracts Organization to Conduct Ph1b Trial in Multiple Myeloma
10 Jul 2023 //
BUSINESSWIRE
Starton Receives Authorization to Proceed with Lenalidomide Phase 1b Trial
12 Jun 2023 //
BUSINESSWIRE
Starton and Healthwell to Present at the Jefferies Healthcare Conference
06 Jun 2023 //
BUSINESSWIRE
Starton & Healthwell Acquisition to Combine and Create Publicly Traded Leader
27 Apr 2023 //
BUSINESSWIRE
Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Reduction
12 Dec 2022 //
GLOBENEWSWIRE
Starton Therapeutics Appoints Moses Dodo to Its Board of Directors
27 Sep 2022 //
EINNEWS
Starton Reports Positive Results from PI Study Evaluating STAR-LLD
13 Jul 2022 //
GLOBENEWSWIRE
Starton`s Approval to Proceed with Final Dose Escalation in PI Study of STAR-LLD
23 May 2022 //
GLOBENEWSWIRE
Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program
04 May 2022 //
GLOBENEWSWIRE
Starton Therapeutics Doses First Subjects in Phase 1 Clinical Trial
25 Apr 2022 //
GLOBENEWSWIRE
Starton Tx Announces FDA Clearance of IND Application for STAR-OLZ TDS in CINV
04 Apr 2022 //
GLOBENEWSWIRE
Starton Tx Successfully Demonstrates Continuous Drug Delivery of Lenalidomide
24 Jan 2022 //
GLOBENEWSWIRE
Starton Tx Receives Clinical Trial Authorization to Initiate Phase 1 Trial
10 Jan 2022 //
GLOBENEWSWIRE
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application
04 Oct 2021 //
GLOBENEWSWIRE
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application
04 Oct 2021 //
GLOBENEWSWIRE
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study
30 Sep 2021 //
GLOBENEWSWIRE
Starton Therapeutics provided update on Phase 2 TROPIC-I Clinical Study
16 Jun 2021 //
GLOBENEWSWIRE
Starton Therapeutics Advances STAR-LLD Transdermal Lenalidomide
09 Jun 2021 //
GLOBENEWSWIRE
Starton Completes Pre-IND Meeting with FDA: Clearing Path to Ph 1 Study
22 Mar 2021 //
GLOBENEWSWIRE
Starton and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement
01 Mar 2021 //
GLOBENEWSWIRE
